Immunohistochemical analysis of molecular biological factors in intraductal papillary-mucinous tumors and mucinous cystic tumors of the pancreas

Scandinavian Journal of Gastroenterology

Volumn 39, Issue 11, 2004, Pages 1159-1165

  Sawai, Hirozumi ^a   Okada, Y ^a   Funahashi, H ^a   Matsuo, Y ^a   Tanaka, M ^a   Manabe, T ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Hormone associated receptor; Integrin; Intraductal papillary mucinous tumor; Mucinous cystic tumor; Pancreatic neoplasm

Indexed keywords

ALPHA6 INTEGRIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLINE; ESTROGEN RECEPTOR; INTERLEUKIN 1 RECEPTOR; MONOCLONAL ANTIBODY; PANCREATIC CANCER ASSOCIATED ANTIGEN 2; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER SURVIVAL; CLINICAL ARTICLE; CYSTADENOMA; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; MUCINOUS CYSTIC TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR DIAGNOSIS; TUMOR LOCALIZATION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CYSTADENOMA, MUCINOUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHA6; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 8844239948     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520410003632     Document Type: Article

References (40)

1. Ohhashi K, Murakami F, Maruyama M. Four cases of mucous secreting pancreatic cancer. Prog Dig Endosc 1982;20:348-51. [in Japanese].
2. Itai Y, Ohhashi K, Nagai H, Murakami Y, Kokubo T, Makita K, Ohtomo K. 'Ductectatic' mucinous cystadenoma and cystadenocarcinoma of the pancreas. Radiology 1986;16I:697-700.
3. Nagai E, Ueki T, Chijiwa K, Tanaka M, Tsuneyoshi M. Intraductal papillary-mucinous neoplasms of the pancreas associated with so-called 'Mucinous ductal ectasia': histochemical and immunohistochemical analysis of 29 cases. Am J Surg Pathol 1995;19:576-89.
4. Rickaert F, Cremer M, Devière J, Tavares L, Lambilliotte JP, Schroder S, et al. Intraductal mucin-hypersecreting neoplasms of the pancreas: a clinicopathologic study of eight patients. Gastroenterology 1991;101:512-9.
5. Yamaguchi K, Tanaka M. Mucin-hypersecreting tumor of the pancreas with mucin extrusion through an enlarged papilla. Am J Gastroenterol 1991;86:835-9.
6. Yamada M, Kozuka S, Yamano K, Nakazawa S, Haitoh Y, Tsukamoto Y. Mucin-producing tumor of the pancreas. Cancer 1991;68:159-68.
7. Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma): a clinicopathologic study of 41 cases. Am J Clin Pathol 1978;69:573-80.
8. Hodgkinson DJ, ReMine WM, Weiland LH. Pancreatic cystadenoma: a clinicopathologic study of 45 cases. Arch Surg 1978;113:512-9.
9. Wada Y. Mucinous cystic tumors, non-invasive and invasive. In: Pour PM, Konishi T, Klöppel G, et al, editors. Atlas of exocrine pancreatic tumors. Tokyo: Springer-Verlag; 1994. p. 67-82.
10. Klöppel G, Solcia E, Longnecker DS, Cappella C, Sobin LH. Histological typing of tumors of the exocrine pancreas. World Health Organization. International histological classification of tumors. 2nd ed. Berlin: Springer; 1996.
11. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, et al. Intraductal papillary-mucinous tumors represent a distinct group of pancreatic neoplasms: an investigation of tumor cell differentiation and K-ras. p53 and c-erbB-2 abnormalities in 26 patients. Virch Arch 1994;425:357-67.
12. Fukushima N, Mukai K, Kanai Y, Hasebe T, Shimada K, Ozaki H, et al. Intraductal papillary tumors and mucinous cystic tumors of the pancreas: clinicopathologic study of 38 cases. Hum Pathol 1997;28:1010-7.
13. Z'graggen K, Rivera JA, Compton CC, Pins M, Werner J, Fernandez-del Castillo C, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 1997;226:498-500.
14. Loftus EV, Jr, Olivares-Pakzad BA, Batts KP, Adkins MC, Stephens DH, Sarr MG, et al. Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of the Mayo Clinic. Gastroenterology 1996 110:1909-18.
15. Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003;90:1244-9.
16. Sugiyama M, Atomi Y, Kuroda A. Two types of mucin-producing cystic tumors of the pancreas: diagnosis and treatment. Surgery 1997;122:617-25.
17. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:51-60.
18. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Bucheler MW. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996;74:35-42.
19. Wyllie FS, Dawson T, Bond JA, Goretzki P, Game S, Prime S, et al. Correlated abnormalities of transforming growth factor-beta response and p53 expression in thyroid epithelial cell transformation, Mol Cell Endocrinol 1991;76:13-21.
20. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, et al. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998;43:414-21.
21. Nio Y, Iguchi C, Yamasawa K, Sasaki S, Takamura M, Toga T, et al. Apoptosis and expression of bcl-2 and bax proteins in invasive ductal carcinoma of the pancreas. Pancreas 2001;22:230-9.
22. Tomoszewska R, Karcz D, Stachura J. An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplasia and pancreatic cancer. Int J Pancreatol 1999;26:163-71.
23. Vogelmann R, Kreuser ED, Adler G, Lutz MP. Integrin α6β1 role in metastatic behavior of human pancreatic carcinoma cells. Int J Cancer 1999;80:791-5.
24. Shaw LM, Chao C, Wewer UM, Mercurio AM. Function of the integrin alpha 6 beta 1 in metastatic breast carcinoma cells assessed by expression of a dominant-negative receptor. Cancer Res 1996;56:959-63.
25. Sawai H, Yamamoto M, Okada Y, Sato M, Akamo Y, Takeyama H, Manabe T. Alteration of integrins by interleukin-1α in human pancreatic cancer cells. Pancreas 2001;23:399-405.
26. Sawai H, Funahashi H, Matsuo Y, Yamamoto M, Okada Y, Hayakawa T, et al. Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig Dis Sci 2003;48:1241-50.
27. Jean LG, Therese T, Stratis A. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979;27:1131-9.
28. Gary SW, Roger W. Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. J Histochem Cytochem 1981;29:1196-204.
29. Motojima K, Tomioka T, Tsunoda T, Kanamatsu T. Immunohistochemical study of pancreatic cystadenocarcinoma. Am J Gastroenterol 1992;87:43-7.
30. Sugiyama M, Atomi Y. Intraductal papillary-mucinous tumors of the pancreas: imaging studies and treatment strategies. Ann Surg 1998;228:685-91.
31. Dedhar S, Hannigan GE. Integrin cytoplasmic interactions and bidirectional transmembrane signaling. Curr Opin Cell Biol 1996;8:657-69.
32. Weinel RJ, Rosendahl A, Pinschmidt E, Kisker O, Simon B, Santoso S. The alpha 6-integrin receptor in pancreatic carcinoma. Gastroenterology 1995;108:523-32.
33. Lan H, Zain R, Saitoh M, Muramatsu Y, Shrestha P, Mori M. Proliferating cell nuclear antigen (PCNA) and p53 in epithelial dysplasia and squamous cell carcinoma of oral mucosa: a marker for poor tumor differentiation, increasing nuclear atypia and invasiveness? Anticancer Res 1996;16:3059-66.
34. Kawahira H, Kobayashi S, Kaneko K, Asano T, Ochiai T. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy. Hepato-Gastroenterology 2000;47:973-7.
35. Jinfeng M, Kimura W, Sakurai F, Moriya T, Takeshita A, Hirai I. Histopathological study of intraductal papillary mucinous tumor of the pancreas. Int J Gastrointest Cancer 2002;32:73-81.
36. Islam H, Fujioka Y, Tomidokoro T, Sugiura H, Takahashi T, Kondo S, et al. Immunohistochemical analysis of expression of molecular biologic factors in intraductal papillary-mucinous tumors of pancreas: diagnostic and biologic significance. Hepato-Gastroenterology 1999;46:2500-5.
37. Izumo A, Yamaguchi K, Eguchi T, Nishiyama K, Yamamoto H, Yonemasu H, et al. Mucinous cystic tumor of the pancreas: immunohistochemical assessment of Ovarian-type stroma'. Oncol Rep 2003;10:515-25.
38. Yeh TS, Jan YY, Chiu CT, Ho YB, Chen TC, Lee KF, et al. Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Gut 2002;51:712-6.
39. Singh S, Baker PR, Poulsom R, Wright NA, Sheppard MC, Langman MJ, et al. Expression of oestrogen receptor and oestrogen-inducible genes in pancreatic cancer. Br J Surg 1997;84:1085-9.
40. Fukushima N, Mukai K. Ovarian-type' stroma of pancreatic mucinous cystic tumor expresses smooth muscle phenotype. Pathol Int 1997;47:806-8.